ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2272

Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry
Abstract Number: 2608

Evolution of Rheumatoid Arthritis Pharmacotherapy: A Ten-Year Analysis of Biologic and Targeted Synthetic DMARD Use and Its Predictors in a National Sample of Rheumatology Practices
Abstract Number: 2202

Evolving Phenotypic and Genotypic Spectrum of Human ISG15 and USP18 Deficiencies
Abstract Number: 1954

Examination of Rehabilitation Referrals from Rheumatology Practices for Adults with Rheumatoid Arthritis in the RISE Registry: A Feasibility and Descriptive Study
Abstract Number: 2588

Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents
Abstract Number: 1290

Examining the Quality of Surveys Used in Rheumatology Health Professions Education Research
Abstract Number: 1850

Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Abstract Number: 2516

Exome-Wide Rare Variant Association Study of Takayasu’s Arteritis
Abstract Number: 0095

Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Abstract Number: 2074

Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy
Abstract Number: 1176

Exploration of Heterogeneity of Treatment Effects Across Exercise-Based Interventions for Knee Osteoarthritis
Abstract Number: 0364

Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Abstract Number: 2315

Exploring Antibodies in Psoriatic Arthritis: A Novel Autoimmune Biomarker Discovered
Abstract Number: 2162

Exploring Barriers to Rheumatoid Arthritis Treatment Changes: Insights into Patient Concerns
Abstract Number: 0165

Exploring Changes in Daily Behaviors with Changes in Physical Function over 24 Weeks in Adults with Knee OA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].